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Abstract
Non-coding RNAs are a species of RNA that are not translated to proteins. These 
include transfer RNAs and ribosomal RNAs, microRNAs, transfer RNA-derived 
fragments, and long non-coding RNA. It is known that expression levels of some 
non-coding RNAs included microRNAs are altered in cancer cells or tumor tissues. 
Moreover, expression profiles of such non-coding RNAs correlate between tissues 
and body fluids. Therefore, several non-coding RNAs are being used as diagnostic/
prognosis biomarkers or therapeutic targets in cancer. In this chapter, we review 
about representative non-coding RNAs and introduce especially microRNA as 
diagnosis/prognosis biomarkers and therapeutic targets.
Keywords: microRNA, isomiR, exosome, biomarker, therapeutics
1. Introduction
Non-coding RNAs (ncRNAs) are generic terms of RNA that are not translated 
to protein. For example, ribosomal RNA (rRNA) and transfer RNA (tRNA) are 
included in ncRNAs. In the body, ncRNA does not encode proteins but has impor-
tant functions.
MicroRNAs (miRNA), one of the ncRNAs, are small non-coding RNAs with an 
average length of 22 nucleotides. miRNA is transcribed from genomic DNA, the 
transcribed miRNA is called “primary microRNA (pri-miRNA),” which is long tran-
scripts having stem-loop structures. Pri-miRNA is processed by Drosha and DGCR8 
(DiGeorge syndrome critical region 8), one of the microprocessors, to “precursor 
miRNA (pre-miRNA).” In the next step, there is pre-miRNA transition from nuclei 
to the cytoplasm through Exportin-5. Cytoplasmic pre-miRNA is processed by 
Dicer, one of RNaseIII, to double-strand miRNA. The double-strand miRNA binds 
to AGO (Argonaute) protein and forms RISC (RNA-induced silencing complex). 
RISC binds 3′ UTR (3′ untranslated region) of target mRNAs, and downregulate 
gene expression via mRNA cleavage, translational repression, or mRNA degrada-
tion (Figure 1) [1]. Recently, it is known that miRNA also binds to 5′ UTR (5′ 
untranslated region) and CDS (coding sequence) of target mRNAs [2, 3]. miRNAs 
may have over hundreds of target genes, regulating various biological phenomena. 
In cancer patients, many miRNAs are aberrantly expressed, caused by chromosomal 
aberration, epigenetic regulation, and genomic mutation [4–6]. Therefore, miRNAs 
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with altered expression under pathological conditions are valuable for biomarkers 
and targets of therapeutics.
Interestingly, recent studies revealed that miRNA sequences have the variation 
compared with the reference sequences. As miRNAs are called isomiRs, isomiRs 
are the miRNA variants that have different sequences and/or lengths [7–10]. These 
isomiRs are classified as 5′ isomiR, 3′ isomiR, and polymorphic isomiR. isomiRs are 
generated through the slice site variation by Drosha or Dicer, the nucleotide addi-
tion, RNA editing, etc. [11]. Some isomiRs are abnormally expressed in cancer cells 
caused by chromosomal and/or miRNA processing aberration (Figure 2) [12, 13]. 
Thus, isomiR is also focused on as novel biomarker for cancer detection.
Long non-coding RNA (lncRNA) that is also one of ncRNAs consisting of over 
200 nucleotides has multiple functions. LncRNA up- or downregulation has been 
shown to regulate several biological processes, such as transcription, translation, 
epigenetic modification, and miRNA expression [14]. It has been shown that 
lncRNA expressions are altered in various diseases. Therefore, similar to miRNAs, 
lncRNA has the potential of biomarkers and therapeutics. Moreover, recently it 
Figure 1. 
The overview of miRNA biogenesis. miRNA is transcribed from genomic DNA to primary miRNA (pri-
miRNA), which is long transcripts having stem-loop structures. Pri-miRNA is processed by Drosha and 
DGCR8 (DiGeorge syndrome critical region 8), one of the microprocessors, to precursor miRNA (pre-miRNA). 
After the transition of pre-miRNA from nuclei to the cytoplasm through Exportin-5, cytoplasmic pre-miRNA 
is processed by TRBP (transactivation response RNA-binding protein) and dicer, one of RNaseIII, to double-
strand miRNA. The double-strand miRNA binds to AGO (Argonaute) protein and forms RISC (RNA-induced 
silencing complex). RISC binds 3′ UTR (3′ untranslated region) of target mRNAs.
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Figure 2. 
The classification and generation of isomiRs. The isomiRs have a different length or sequence with mature 
miRNAs. These isomiRs are generated by a variation of Drosha or dicer variation. The aberrant processing 
in 5′ site generates 5′ isomiR. On the other hand, 3′ isomiR is generated by the aberrant processing in 3′ site. 
Polymorphic isomiR is generated by RNA editing. Navy arrow shows the correct processing site. Magenta and 
green arrows show the aberrant processing sites for isomiRs, which have a longer length. Orange and blue 
arrows show the aberrant processing sites for isomiRs, which have a shorter length. The red bar indicates the 
variati of sequence.
Figure 3. 
The classification and various modes of generation of tRFs. tRNA-derived fragments (tRFs) are generated by 
cleavage of transfer RNA (tRNA). 1-tRFs are cleaved from pre-tRNA. The cleavage of the D-loop generates 
5′-tRF. The cleavage of the T-loop generates 3′-tRF. 5′- and 3′-tRNA-derived stress-induced RNAs (tiRNAs) are 
generated by cleavage of the anticodon loop.
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was uncovered that tRNA fragments are functional. Its non-coding RNA is called 
at tRNA-derived RNA fragment (tRF), and classified as 1-tRF, which is generated 
from the 3′-end of pre-tRNA, 5′-tRFs, which is generated by the cleavage of 5′ 
end in D-loop, 3′-tRFs, which is generated by the cleavage of 3′ end in T-loop, and 
tRNA-derived, stress-induced RNAs (tiRNAs), which is generated by specific cleav-
age in the anticodon loop. Some tRFs are identified as novel biomarkers for disease 
diagnosis (Figure 3) [15].
2. Liquid biopsy
A biopsy is a method for disease diagnosis using a part of tissues or cells of the 
lesion. The tissue specimens are sampled by surgery and the cells derived from the 
lesion are sampled by fine-needle aspiration. The biopsy is useful for diagnosing 
diseases and malignancies, because it is possible to observe tissues or cells directly.
Generally, to diagnose breast cancer, inspection, palpation, and mammography 
are performed at first. Then, if the patients are suspected of tumors, the biopsies 
using tissue or cells derived from the lesion are performed, resulting in diagnosing 
breast cancer. However, conventional biopsy, surgery, needle biopsy, fine-needle 
aspiration, etc., are high invasiveness and have the risk of needle tract seeding. As 
with other problems, it is also concerned that young women are diagnosed as false 
positive on mammography, caused by high breast density.
Recently, to solve a problem like this, some researchers focus on “liquid biopsy.” 
Liquid biopsy is the method for disease diagnosis using body fluid. Body fluids 
using in the liquid biopsy are mainly blood, but also saliva, urine, and spinal fluid 
[16, 17]. Because using body fluid like blood, sampling the specimen is capable of 
low invasiveness and repetitive. These are one of the features and usefulness of 
liquid biopsy. In the field of cancer research, circulating tumor cells (CTCs) and 
circulating cell-free DNAs (cfDNAs) are detected and evaluated, resulting in the 
diagnosis of cancers. However, a recent study uncovered that circulating miRNA in 
body fluid is reflected in pathology. Many researchers show that specific miRNAs 
are aberrantly expressed in each disease. More interestingly, some miRNA expres-
sions are altered from an early stage of cancer. Therefore, investigating the altera-
tion of miRNA expression leads to the early diagnosis of cancer.
2.1 Circulating tumor cells (CTCs)
The cancer cells leak to the bloodstream from the primary tumor in the tumor 
metastasis phase. In the detection of CTCs, cancer cells that are derived from meta-
static tumors are directly evaluated. However, detecting CTCs is not easy, because 
the number of CTCs is too low. To detect and gather CTCs, cell surface markers are 
recognized by the specific antibodies. Then, evaluating the shape and gene profile 
of cancer cells results in the diagnosis of malignancy and specific mutation of each 
tumor. However, the detection in the early stage of cancer is not useful, because the 
CTCs are detected in the late stage of cancer.
2.2 Cell-free DNAs (cfDNAs)
In the bloodstream, DNA derived from various dead cells containing hematopoi-
etic cells or other cells derived from tissues are circulating. Additionally, it is known 
that DNA fragments derived from cancer cells are circulating in the bloodstream 
of cancer patients. These DNA fragments are generated by apoptosis or clearance 
by immune cells. In the detection of cfDNAs, the tumor-specific somatic mutation 
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is detected, resulting in the diagnosis of cancer. However, the detection of cfDNA 
derived from cancer cells is not useful for the early diagnosis of cancer, because 
cfDNAs were derived from the dead cells.
2.3 Non-coding RNAs (ncRNAs)
Recent studies have uncovered that the ncRNAs included miRNAs, tRFs, and 
other ncRNAs circulate in different body fluids [15, 18]. Generally, circulating RNAs 
are easily degraded by RNase present in plasma. However, ncRNAs secreted to body 
fluids via extracellular vesicles like exosomes, or bound to proteins, are resistant to 
RNase and therefore can be stable in circulation. Exosomes are a type of extracel-
lular vesicles, ranging in size from 50 to 150 nm. Exosomes that are secreted from 
donor cells circulate in the body fluids and are transferred to target recipient cells. 
The uptake of exosomes in recipient cells leads to various physiological functions. 
These functions are caused by ncRNAs and/or proteins contained in exosomes. In 
this regard, it is thought that exosomes are required for cell-to-cell communica-
tions. For example, it is reported that miRNA contained in exosomes secreted from 
cancer cells, contributing to the metastasis of cancer [19]. Recently, it is thought 
that exosomes derided from cancer cells educate metastasis site and help the cancer 
metastasis via the transfer of ncRNA and protein as like this report [20]. Moreover, 
recent studies uncovered that circulating ncRNA in body fluid is reflected in the 
pathology. Many researchers show that specific miRNAs are aberrantly expressed in 
each disease. More interestingly, some miRNA expressions are altered from an early 
stage of cancer. Therefore, investigating the alteration of miRNA expression leads to 
the early diagnosis of cancer. In this regard, many researchers focus on the ncRNAs 
circulating in the body fluids. In particular, miRNAs circulating in the blood are 
focused on.
3. The method of screening the ncRNAs in the liquid biopsy
In liquid biopsy, there are several methods of screening for the circulating 
ncRNAs in the body fluids. In the case of using blood, commonly, it is necessary 
to isolate plasma or serum from blood. Then, RNA purification is performed from 
plasma or serum. Using purified RNA, the expression profiles of ncRNAs are 
assessed by real-time PCR or microarray, resulting in the identification of a novel 
biomarker. Examples are shown below:
3.1 Real-time PCR
In the method using real-time PCR, the specific ncRNA is detected with its 
primer pair, and the alteration of the ncRNA expression is evaluated. The real-time 
PCR method is not suited for screening and identification of a novel biomarker, 
because of using the specific primer pair corresponding to each ncRNAs. On the 
other hand, this method is available for detecting the already identified ncRNA or 
the particular ncRNA, because the experimental procedure is easier and the detec-
tion sensitivity is more specific than other methods.
3.2 Microarray
In the method using microarray, the alteration of ncRNAs existing on microar-
ray chips is capable of a comprehensive evaluation, because the multiple ncRNAs 
are detectable at the same time. In the microarray method, the ncRNA expression 
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is detected by the binding between cDNAs synthesized from RNA and probes 
anchored to the microarray chip. Therefore, the microarray method is not available 
for unknown ncRNAs.
3.3 Next-generation sequencing (NGS)
In the NGS, the alteration of ncRNA expression is comprehensively evaluated by 
direct reading the RNA sequence of whole ncRNAs. In this regard, it is possible to 
identify and compare the expression pattern of ncRNAs like as microarray method. 
Additionally, it is also possible to identify unknown ncRNAs because of the directly 
determining ncRNA sequence. Moreover, isomiRs, that many researchers recently 
focused on, are also detectable. However, experimental procedures and data analy-
ses are more difficult and complex than the other methods, and the experimental 
cost is also high.
4. microRNA for breast cancer diagnosis
Some miRNAs are altered in the tumor tissue compared with normal tissue. For 
example, the expression level of miR-21 is increased in various cancers included 
breast cancer and associated with tumorigenesis. Additionally, some miRNAs have 
a specific expression level in breast cancers. Recent studies also reported that the 
expression of some miRNAs is altered by the difference of subtype or stage and 
with/without the receptors. Furthermore, it is known that some of these miRNAs 
are circulating in body fluids. Therefore, such miRNAs are available for the bio-
markers in liquid biopsy. Specific ncRNAs are described below, and recent reports 
are summarized in Table 1.
4.1 Circulating miRNAs
Francesca Maria Orlandella and colleagues focused on miR-622 that known to 
act as a tumor suppressor in several types of cancer. They reported that miR-622 
was downregulated in the plasma and tissues of breast cancer patients. Moreover, it 
was revealed that the expression level of miR-622 correlated with the breast cancer 
subtypes and the advance of tumor stages. Additionally, miR-622 inhibited the 
migration of breast cancer cells via targeting NUAK family kinase 1 (NUAK1). In 
this regard, circulating miR-622 is useful for the biomarker of breast cancer [27].
To identify miRNAs that are useful for the early diagnosis of invasive breast 
cancers, Mio Yoshikawa and colleagues screened exosomal miRNAs of the plasma by 
microarray analysis. Using exosomal miRNAs of ductal carcinoma in situ (DCIS) and 
invasive ductal carcinoma (IDC), five miRNAs, miR-223-3p, miR-130-3p, miR-
191-5p, miR-146a, and miR-221-3p, were upregulated in IDC compared with healthy 
control and DCIS. In this study, they revealed that the expression level of miR-223-3p 
was correlated between the tissue and plasma exosome. Furthermore, the expres-
sion level of miR-223-3p was upregulated according to the advance of tumor stages. 
In these findings, it is suggested that the expression level of exosomal miR-223-3p 
reflected the tissue pathogenesis, and the miR-223-3p has the potential as a biomarker 
for early diagnosing of invasive lesions from DCIS patients in liquid biopsy [37].
4.2 isomiR
Yumiko Koi and colleagues investigated the comprehensive expression profile 
of ncRNA using the NGS method and focused on the expression level of isomiR. 
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NcRNAs Source Alteration Method Characters Reference
Let-7i Urine Down qRT-PCR Down in breast cancer [21]
miR-15a Serum Down qRT-PCR Down in TNBC [22]
miR-17 Serum Down qRT-PCR Down in TNBC [22]
miR-18a Serum
Urine
Down qRT-PCR Down in TNBC [22]
miR-19b Serum Down qRT-PCR Down in TNBC [22]
miR-30b Serum
Urine
Down qRT-PCR Down in TNBC [22]
miR-92a Serum Down qRT-PCR Down during tumor 
progression
[23]
miR-145 Plasma Down Microarray Down in breast cancer [24]
miR-194-5p Plasma Down NGS Down in brain metastasis [25]
miR-195 Plasma Down NGS Down in metastatic breast 
cancer
[26]
miR-222 Urine Down qRT-PCR Down in TNBC [22]
miR-320c Urine Down qRT-PCR Down in TNBC [22]
miR-423 Urine Down qRT-PCR Down in breast cancer [21]
miR-622 Plasma Down qRT-PCR Down in breast cancer [27]
miR-660 Urine Down qRT-PCR Down in breast cancer [21]
miR-802-5p Plasma Down NGS Down in brain metastasis [25]
Let-7a Serum Up qRT-PCR Up in TNBC [22]
Let-7e Serum Up qRT-PCR Up in TNBC [22]










Serum Up NGS Up in breast cancer [29]
miR-23a-3p Serum Up NGS Up in breast cancer [29]
miR-29c Serum Up qRT-PCR Up in early breast cancer [30]
miR-99a-5p Plasma Up qRT-PCR Up in early breast cancer [31]









Up in luminal A breast cancer 
and TNBC
[32, 33]
miR-155 Serum Up qRT-PCR
Microarray
Up in breast cancer
Prognostic biomarker (drug 
resistance)
[34, 35]
miR-199a Serum Up qRT-PCR Up in early breast cancer [30]
miR-210 Plasma Up qRT-PCR Up in breast cancer [36]
miR-223-3p Plasma Up Microarray Up during tumor progression [37]







qRT-PCR Up in early breast cancer [21, 30]
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They used the exosomal RNA of serum derived from breast cancer patients. At 
first, they revealed that 11 circulating small RNAs were upregulated in breast 
cancer serum compared with healthy controls. Then, 3′-isomiR of miR-21-5p 
was identified as one of the biomarkers for the diagnosis of breast cancer. 
Additionally, miR-23a-3p and tRF-Lys-TTT were also identified as biomarkers for 
the diagnosis of breast cancer. Interestingly, they proposed a discriminant model 
using the expression levels of these small ncRNAs, and this model was more 
significantly able to diagnose breast cancer than individual small ncRNA. It was 
revealed that this model was able to diagnose the stage 0 breast cancer. Moreover, 
the model also could diagnose the breast cancer irrespective of subtypes. In this 
regard, the model that included the alteration of isomiR is available for the early 
diagnosis of breast cancer [29].
4.3 tRFs
As mentioned above, it is clear that tRFs are generated in cancers. Yue Huang 
and colleagues investigated the expression profile of tRFs in normal breast epithe-
lial cell lines and non-triple negative breast cancer (non-TNBC) cells using RNA 
sequencing. In further investigation, they revealed that the expression level of 
tDR-7816 (drives from tRNAGln−CTG−3−1), tDR-5334 (derived from tRNAGly−CCC−5−1), 
and tDR-4733 (derived from tRNAPhe−GAA−2−1) is altered in the serum of non-TNBC 
patients compared with healthy controls. It is suggested that these tRFs are useful 
for the diagnosis of breast cancer [40].
In addition, Jingyi Wang and colleagues explored the expression profiles 
of tRFs in plasma derived from breast cancer patients. As the result, six tRFs, 
tRF-Glu-CTC-003, tRF-Gly-CCC-007, tRF-Gly-CCC-008, tRF-Leu-CAA-003, 
tRF-Ser-TGA-001, and tRF-Ser-TGA-002, were altered in the early stage of breast 
cancers compared with healthy controls. These six tRFs are also downregulated in 
the plasma derived from DCIS. Moreover, they also revealed that these tRFs which 
excluded tRF-Glu-CTC-003 in HER2+ type and tRF-Gly-CCC-008 in luminal type 
are downregulated in each subtype. In this regard, it is suggested that these tRFs are 
useful as a novel biomarker for the diagnosis of early-stage breast cancer [41].
NcRNAs Source Alteration Method Characters Reference
miR-451 Plasma Up Microarray Up in breast cancer [24]
miR-488 Serum Up Microarray Prognostic biomarker 
(recurrence)
[38]
miR-576-3p Plasma Up NGS Prognostic biomarker 
(recurrence)
[33]
miR-1246 Serum Up Microarray Prognostic biomarker (drug 
resistance)
[35]
miR-1910-3p Serum Up qRT-PCR Up in breast cancer [39]
miR-4433b-5p Serum Up NGS Up in luminal A breast cancer 
and TNBC
[32]
miR-4665-5p Plasma Up NGS Prognostic biomarker 
(recurrence)
[33]
“Up” indicates upregulation in breast cancer and “Down” indicates downregulation in breast cancer. qRT-PCR, 
quantitative reverse transcription-polymerase chain reaction; NGS, next-generation sequencing; TNBC, triple-
negative breast cancer.
Table 1. 
The alteration of circulating miRNAs in breast cancer.
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4.4 Urinary miRNAs
In the liquid biopsy, urine as the specimens has the advantage of easy and 
non-invasive collection. Thalia Erbes and colleagues investigated whether miRNAs 
in serum/plasma that are already identified as the candidates of biomarkers for 
breast cancer are altered in also urine [42]. The expression level of miR-155 which 
is known to be upregulated in serum from the breast cancer patients, and useful 
for the diagnostic biomarker, was upregulated also in urine from the breast cancer 
patients [42, 43]. Moreover, they revealed that the expression levels of urinary 
miR-21, miR-125, and miR-451 were also downregulated in the breast cancer 
patients like serum miRNAs [24, 42, 44, 45]. In the recent study, it is revealed that 
the expression level of urinary miR-423, miR-424, miR-660, and let-7i was altered 
in the breast cancer patients compared with healthy controls. Moreover, this study 
reported that the combination of these miRNA’s alterations more significantly 
diagnoses the breast cancer than the biomarker using individual miRNA’s alteration 
[21]. In this regard, urinary miRNAs are useful for the diagnostic and prognosis 
biomarkers.
5. microRNA for breast cancer therapeutics
As mentioned above, the expression level of various miRNAs is dramatically 
altered in the development and progression of diseases including the tumors. In 
this regard, it is thought that the alteration of miRNA expression contributes to the 
development and progression of several diseases. Moreover, the expression profiles 
of miRNAs are different in each type of diseases. Then, such miRNAs are available 
for the therapeutic target of the disease. In cancer research, miRNAs that are over-
expressed in tumors are called “oncogenic microRNA (OncomiR)”, and are associ-
ated with tumor development and malignancy. On the other hand, miRNAs that are 
downregulated in tumors are called at “tumor suppressive microRNA (TS-miRNA)” 
and are contributed to the suppression of tumor progression via targeting genes 
that are associated with the cancer cell proliferation and survival. It is hoped that 
miRNA mimics and miRNA inhibitors targeting TS-miRNA or OncomiR are devel-
oped as therapeutic drugs. Specific ncRNAs are described below, and recent reports 
are summarized in Table 2.
5.1 miR-22
It is reported that a lot of miRNAs regulate tumor progression and malignancy. 
Previously, we revealed that miR-22, which induce cellular senescence, sup-
pressed the proliferation of breast tumors. MiR-22 is upregulated during cellular 
senescence induction. Such miRNAs are called “senescence-associated microRNA 
(SA-miRNA).” We reported that miR-22 induces cellular senescence via targeting 
CDK6 and SIRT1. Moreover, it was suggested that miR-22 was the therapeutic target 
of breast cancer, because miR-22 was downregulated in the breast cancer cells. In an 
additional investigation, it is reported that the replacement of miR-22 expression 
repressed the breast tumors through the experiment using the xenograft model 
mouse model [56].
5.2 miR-155
Jiang and colleagues reported that the expression level of miR-155 was upregu-
lated in breast cancer. Then, they suggested that miR-155 functions as OncomiR, 
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because its target gene is a suppressor of cytokine signaling 1 (SOCS1) known as 
one of the tumor suppressor genes. This study revealed that the inhibition of the 
miR-155 expression and function by the antisense oligonucleotide against miR-155 
repressed the tumor progression in the investigation using both the breast cancer 
cells and the xenograft mouse models. In this regard, the inhibition of OncomiR 
functions is available for the therapeutic targets [57].
5.3 miR-424/503 cluster
It is reported that the miR-424/503 cluster that was coded on X-chromosome 
was deficient in luminal B breast cancer. It is also clear that the deletion of this 
locus significantly correlated with the poor prognosis. Therefore, it is suggested 
that the miR-424/503 cluster functions as TS-miRNA. Moreover, the miR-424/503 
cluster targets insulin-like growth factor 1 receptor (IGF1R) and B-cell lymphoma 
2 (BCL-2) that contribute to anti-apoptosis. The deletion of this cluster leads to 
upregulating these gene expressions, resulting in the acquisition of drug resis-
tance [58].
5.4 miR-539
A recent study reported that miR-539 was downregulated in tumor tissues, 
and it is suggested that miR-539 has the tumor suppressive effects. In the investi-
gation using breast cancer cells, miR-539 mimics repressed the proliferation and 
migration of cancer cells via targeting epithelial growth factor receptor (EGFR). 
Additionally, miR-539 also repressed the tumor proliferation [59]. Moreover, it is 
uncovered that miR-539 was downregulated in TNBC, and miR-539 suppressed 
the proliferation, invasion, and migration via targeting Laminin subunit alpha 4 
(LAMA4) [60].
ncRNAs Types Targets Functions Reference
miR-429 Anti-sense 
oligonucleotide
VHL Inhibit the proliferation of HER2+ 
breast cancer
[46]
miR-302b inhibitor RUNX2 Inhibit the proliferation [47]
miR-532-5p inhibitor RERG Inhibit the proliferation and 
migration
[48]
miR-1910-3p inhibitor MTMR3 Inhibit proliferation and migration [39]
miR-99a mimic FGFR3 Inhibit the tumor proliferation and 
migration
[49]
miR-128-3p mimic NEK2 Inhibit tumorigenicity and tumor 
growth of breast cancer stem cells
[50]
miR-188-5p mimic RAP2C Induce apoptosis and inhibit the 
proliferation
[51]
miR-299-5p mimic STK39 Inhibit the migration and invasion [52]
miR-342 mimic CFL1 Inhibit the migration and invasion [53]
miR-424-5p mimic PD-L1 Induced apoptosis and cell cycle 
arrest
[54]
miR-590-3p mimic SLUG Inhibit the metastasis in TNBCs [55]
HER2, human epidermal growth factor receptor 2; TNBCs, triple-negative breast cancers.
Table 2. 
The miRNAs as therapeutic targets in breast cancer.
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5.5 miR-142
It is reported that miR-142 is also downregulated in breast tumor tissue com-
pared with normal tissue and suggested that miR-142 functions as TS-miRNA. It is 
revealed that miR-142 inhibits the expression of the BTB domain and CNC homolog 
1 (BACH1), which is associated with the metastasis of breast cancer, resulting in the 
suppression of the proliferation, invasion, and migration. Moreover, Mansoori and 
colleagues reported that miR-142 induced apoptosis via targeting estrogen recep-
tor 1 (ESR1) that coded estrogen receptor in the estrogen receptor-positive breast 
cancer [61, 62].
5.6 miR-34a
miR-34a is the most famous TS-miRNAs that was reported to upregulate in 
the p53-dependent manner and downregulate in the colorectal cancer patients 
compared with healthy, and progressed in the development as the nucleic acid 
drug against cancer. MiR-34a suppressed colorectal cancer progression through the 
induction of cellular senescence via E2F pathway [63]. In further investigation, it is 
uncovered that miR-34a downregulates the gene expression via targeting sirtuin 1 
(SIRT1), cyclin D1, cyclin-dependent kinase 4/6 (CDK4/6), and MYC [64–66]. In 
this regard, the clinical trial of MRX34, the liposomal miR-34a mimic, for vari-
ous solid tumors included breast cancer was performed in miRNA Therapeutics 
Inc. Unfortunately, this clinical trial was dropped [67]. However, a recently study 
reported that miR-34a targets programmed death ligand 1 (PD-L1) in acute myeloid 
leukemia [68]. Moreover, it is reported that miR-34a expression level is downregu-
lated in TNBC and inversely correlated with PD-L1 expression [69]. Therefore, a 
novel clinical trial of miR-34a is expected.
6. Conclusions
In this review, we summarized several ncRNAs that are available for the bio-
markers diagnosing breast cancer or predicting poor prognosis and the targets of 
breast cancer therapeutics. The finding and studying of isomiRs or tRFs are leading 
to the development of highly specific biomarkers, which could lead to early diag-
nosis of breast cancer. Moreover, it is useful for comparing the alteration of several 
ncRNA expressions multidimensionally with the comprehensive analysis of the 
expression profiles of ncRNAs using microarray or NGS method. These approaches 
and results may lead to highly specific diagnostics of the disease and can correctly 
predict several different types of breast cancers. In regard to cancer therapeutics, 
the studies about isomiRs or tRFs may result in the development of novel therapeu-
tic targets for breast cancers. Further research on the ncRNAs will aid to improve 
the diagnosis and therapeutics of breast cancers.
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